Successful Early Discharge and Avoided Hospitalization for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Treated with Outpatient Parenteral Antimicrobial Therapy (OPAT) Result in Healthcare Cost Savings

Presented on October 24, 2016

Robin H. Dretler, MD, FIDSA – Infectious Disease Specialists of Atlanta, PC, Decatur, GA
Quyen Luu, MD, Macon, GA
Richard C. Prokesch, MD, FACP, FIDSA – Infectious Diseases Associates, Riverdale, GA
Andrew H. Krinsky, MD – Infectious Diseases Associates, Sarasota, FL
H. Barry Baker, MD, FACP – Infectious Disease Physicians, Miami, FL
Claudia P. Schroeder, PharmD, PhD – Healix Infusion Therapy, Inc., Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc., Sugar Land, TX

View Poster View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.